CN111714551B - Preparation method of stranguria-treating preparation - Google Patents
Preparation method of stranguria-treating preparation Download PDFInfo
- Publication number
- CN111714551B CN111714551B CN201911015428.2A CN201911015428A CN111714551B CN 111714551 B CN111714551 B CN 111714551B CN 201911015428 A CN201911015428 A CN 201911015428A CN 111714551 B CN111714551 B CN 111714551B
- Authority
- CN
- China
- Prior art keywords
- ethanol
- preparation
- herba
- stranguria
- filtering
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 41
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 126
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 50
- 239000000284 extract Substances 0.000 claims abstract description 49
- 241000764065 Persicaria capitata Species 0.000 claims abstract description 32
- 240000007019 Oxalis corniculata Species 0.000 claims abstract description 19
- 235000016499 Oxalis corniculata Nutrition 0.000 claims abstract description 19
- 239000003814 drug Substances 0.000 claims abstract description 17
- 238000000034 method Methods 0.000 claims abstract description 13
- 239000012535 impurity Substances 0.000 claims abstract description 11
- 239000002994 raw material Substances 0.000 claims abstract description 5
- 238000001914 filtration Methods 0.000 claims description 32
- 239000000706 filtrate Substances 0.000 claims description 27
- 239000000843 powder Substances 0.000 claims description 25
- 239000008187 granular material Substances 0.000 claims description 23
- 238000002156 mixing Methods 0.000 claims description 16
- 239000006228 supernatant Substances 0.000 claims description 15
- 238000010992 reflux Methods 0.000 claims description 14
- 235000003805 Musa ABB Group Nutrition 0.000 claims description 13
- 240000008790 Musa x paradisiaca Species 0.000 claims description 13
- 235000015266 Plantago major Nutrition 0.000 claims description 13
- 239000008213 purified water Substances 0.000 claims description 13
- 238000001035 drying Methods 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 10
- 238000005520 cutting process Methods 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 6
- 238000010298 pulverizing process Methods 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 2
- 229940100688 oral solution Drugs 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 12
- 238000001556 precipitation Methods 0.000 abstract description 12
- 210000002700 urine Anatomy 0.000 description 15
- 238000000605 extraction Methods 0.000 description 14
- 238000005303 weighing Methods 0.000 description 13
- 239000000243 solution Substances 0.000 description 11
- 238000001291 vacuum drying Methods 0.000 description 10
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 8
- 241000772044 Boenninghausenia Species 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 8
- OBHRVMZSZIDDEK-UHFFFAOYSA-N urobilinogen Chemical compound CCC1=C(C)C(=O)NC1CC1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(CC3C(=C(CC)C(=O)N3)C)N2)CCC(O)=O)N1 OBHRVMZSZIDDEK-UHFFFAOYSA-N 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 239000002245 particle Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000002481 ethanol extraction Methods 0.000 description 5
- 238000004806 packaging method and process Methods 0.000 description 5
- 239000000469 ethanolic extract Substances 0.000 description 4
- 229940074391 gallic acid Drugs 0.000 description 4
- 235000004515 gallic acid Nutrition 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 201000008383 nephritis Diseases 0.000 description 4
- 230000001376 precipitating effect Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000013112 stability test Methods 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 238000003809 water extraction Methods 0.000 description 3
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 150000002212 flavone derivatives Chemical class 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 210000002149 gonad Anatomy 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 206010037597 Pyelonephritis acute Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 201000001555 acute pyelonephritis Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical group C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a novel preparation method of a stranguria-treating preparation, which comprises the steps of firstly extracting polygonum capitatum or polygonum capitatum and creeping oxalis for 2 hours by 70% ethanol, then decocting medicinal residues and other raw material medicaments by adding water, and then carrying out water precipitation on the extracted extract to remove impurities, and on the other hand, strictly controlling relative humidity in the preparation forming process, so that the problem of poor dissolubility in the original preparation is solved, and the stability and curative effect of the product are improved.
Description
Technical Field
The invention relates to a preparation method of a stranguria-treating preparation, and belongs to the technical field of medicines.
Background
At present, the stranguria caused by the accumulation of damp-heat such as urinary system infection, urgent micturition, odynuria, unclean urine and the like is a big problem which troubles a plurality of patients, if not taken into consideration, the inflammation is aggravated, and the normal functions of the urinary tract, the gonad, the accessory gonad and the external genitalia are influenced to different degrees, so that the body is more injured. In the prior art, a plurality of medicines for treating stranguria also exist, and stranguria treating granules and stranguria treating capsules are ideal medicines. The stranguria-treating granule is a pure Chinese medicinal preparation prepared from polygonum capitatum, plantain herb, creeping oxalis and chinarue herb according to the reasonable prescription of Miao nationality medication habits and the theory of traditional Chinese medicine, has the functions of clearing away heat and toxic materials and inducing diuresis for treating stranguria, and is used for difficult urination, painful urination, urinary tract infection and the like caused by damp-heat accumulation. CN02134098.6 discloses a common preparation method of the prior stranguria treating preparation, but the method always has the phenomena of poor dissolubility and excessive water content after long-time storage in the production process.
Disclosure of Invention
In view of the above problems, the present invention aims to provide a novel preparation method of a stranguria treating preparation with good dissolubility and higher stability.
The invention is realized by the following technical scheme: the preparation method of the stranguria treating preparation comprises the following raw material medicines in parts by weight: 450g of polygonum capitatum, 225g of plantain, 225g of creeping oxalis and 150g of chinarue; the method specifically comprises the following steps:
Preferably, the stranguria preparation specifically comprises the following steps:
Preferably, the stranguria preparation specifically comprises the following steps:
Compared with the prior art, the invention has the beneficial effects that: provides a new extraction and preparation method of the stranguria treating preparation, can improve the dissolubility (dissolubility) and stability of the product, can also improve the curative effect, and has simple operation and convenient extraction.
The extraction and preparation method of the invention is improved on the basis of the existing extraction method, and the specific method is as follows: extracting herba Polygoni Capitati or herba Polygoni Capitati and herba Oxalidis Corniculatae with ethanol under reflux, decocting the residue and other rest materials in water for 2 times, mixing the ethanol extractive solution and water extract, concentrating to obtain soft extract, and precipitating with water to remove impurities, so as to improve solubility (solubility) of the extract in syrup, oral liquid, and granule, and prevent precipitation, and to ensure qualified and stable water content in granule and capsule, the relative humidity in the environment is controlled below 65%. On one hand, the invention solves the problems of poor dissolubility and excessive water content in the existing product production process, and on the other hand, the polygonum capitatum and/or the creeping oxalis are extracted by alcohol and then by water, so that the gallic acid content can be increased, the total flavone content can be increased, and the curative effect can be improved.
To illustrate the contents and advantages of the present invention, the following tests were also conducted in the present invention, which are intended to illustrate the present invention and in no way limit the scope of the present invention.
Experiment 1: the extraction method comprises the following steps:
the experimental method and the results are as follows by taking gallic acid, total flavone and the paste yield as investigation indexes:
s-1: weighing 900g of polygonum capitatum, 450g of plantain, 450g of creeping oxalis and 300g of boenninghausenia, adding 8 times of water, decocting for 2 times, each time for 1.5 hours, combining the decoctions, filtering, concentrating the filtrate into thick paste with the relative density of 1.30, drying in vacuum, and weighing to obtain the traditional Chinese medicine composition;
s-2: weighing 900g of polygonum capitatum, adding 70% ethanol which is 8 times the weight of the polygonum capitatum, performing reflux extraction for 1.5 hours, filtering, reserving medicine residues, and recovering ethanol from filtrate to obtain ethanol extract for later use; weighing 450g of plantain herb, 450g of creeping oxalis and 300g of chinarue, adding into polygonum capitatum dregs, adding 8 times of water, decocting for 2 times, each time for 1.5 hours, combining decoctions, filtering, adding polygonum capitatum alcohol extract when the filtrate is concentrated to the relative density of 1.10, continuously concentrating to thick paste with the relative density of 1.30, vacuum drying and weighing to obtain the medicine;
s-3: weighing 900g of polygonum capitatum and 450g of creeping oxalis, adding 70% ethanol with the amount of 8 times of that of the polygonum capitatum, refluxing and extracting for 1.5 hours, filtering, and recovering ethanol from the filtrate to obtain ethanol extract for later use; weighing 450g of plantain herb and 300g of chinarue, adding into the polygonum capitatum and creeping oxalis herb residues, adding 8 times of water, decocting for 2 times, each time for 1.5 hours, combining the decoctions, filtering, concentrating the filtrate until the relative density is 1.10, adding the polygonum capitatum and creeping oxalis alcohol extract, continuously concentrating to thick paste with the relative density of 1.30, vacuum drying, and weighing to obtain the traditional Chinese medicine preparation;
s-4: weighing 900g of polygonum capitatum, 450g of plantain, 450g of creeping oxalis and 300g of boenninghausenia, adding 70% ethanol which is 8 times the amount of polygonum capitatum, refluxing and extracting for 1.5 hours, filtering, reserving medicine residues, and recovering ethanol from filtrate to obtain ethanol extract for later use; decocting the residue with 8 times of water for 2 times, each for 1.5 hr, mixing decoctions, filtering, concentrating the filtrate to relative density of 1.10, adding ethanol extractive solution, concentrating to soft extract with relative density of 1.30, vacuum drying, and weighing;
TABLE 1 optimization results table of extraction method
As a result: from the above table, it can be seen that the increase of alcohol extraction on the basis of the original water extraction process can improve the yield of dry paste, and the content of gallic acid can also be increased by more than 60%, and particularly, after the increase of the alcohol extraction process, the content of total flavonoids is increased by 2 times; in addition, experiments show that the results of alcohol extraction of the polygonum capitatum or the polygonum capitatum and the creeping oxalis are not greatly different from the results of alcohol extraction and water extraction of all the medicinal materials, the extraction cost is limited, and finally, the polygonum capitatum or the polygonum capitatum and the creeping oxalis are preferably only subjected to alcohol extraction and then subjected to a water extraction process with the other medicinal materials.
Experiment 2: and (3) testing the dissolubility:
extracting thick paste: weighing 1800g of polygonum capitatum, adding 70% ethanol which is 8 times the weight of the polygonum capitatum, performing reflux extraction for 1.5 hours, filtering, reserving medicine residues, and recovering ethanol from filtrate to obtain ethanol extract for later use; weighing 900g of creeping oxalis, 900g of plantain herb and 600g of boenninghausenia herb, adding into the polygonum capitatum dregs, adding 8 times of water, decocting for 2 times, each time for 1.5 hours, merging the decoctions, filtering, concentrating the filtrate to the relative density of 1.10, adding the polygonum capitatum alcohol extract, and continuously concentrating to the thick paste with the relative density of 1.30 for later use;
screening by a water sedimentation process:
w-1: directly taking the thick paste, vacuum drying, adding a proper amount of sugar powder, and preparing the stranguria treating granules W1;
w-2: adding 4 times of purified water into the thick paste, performing water precipitation for 24 hours, concentrating the supernatant into thick paste, vacuum drying, adding a proper amount of sugar powder, and preparing the stranguria treating granules W2;
w-3: adding 6 times of purified water into the thick paste, performing water precipitation for 24 hours, concentrating the supernatant into thick paste, vacuum drying, adding a proper amount of sugar powder, and preparing the stranguria treating granules W3;
w-4: adding 8 times of purified water into the thick paste, performing water precipitation for 24 hours, concentrating the supernatant into thick paste, vacuum drying, adding a proper amount of sugar powder, and preparing the stranguria treating granules W4;
w-5: adding ethanol into the soft extract to make ethanol content reach 40%, precipitating with ethanol for 24 hr, collecting supernatant, recovering ethanol, concentrating into soft extract, vacuum drying, adding appropriate amount of sugar powder, and making into stranguria treating granule W5;
w-6: adding ethanol into the soft extract to make the ethanol content reach 60%, precipitating with ethanol for 24 hr, collecting supernatant, recovering ethanol, concentrating into soft extract, vacuum drying, adding appropriate amount of sugar powder, and making into stranguria treating granule W6;
w-7: adding 6 times of purified water into the soft extract, precipitating with water, refrigerating at 2-8 deg.C, standing for 24 hr, collecting supernatant, concentrating into soft extract, vacuum drying, adding appropriate amount of sugar powder, and making into stranguria treating granule W7;
the solubility was used as an index to investigate the effect of different purification methods on solubility, and the results are shown in table 2:
table 2: comparison table of solubility of the present invention and commercially available stranguria treating granules
As a result: as can be seen from the table, the original process has poor solubility, and the solubility is obviously improved after the extracted thick paste is subjected to water precipitation or alcohol precipitation. Through tests, when water is precipitated, 6 times of water is properly added, less water is used, layering is not easy, more water is used, concentration is troublesome, and when water is precipitated, the water can be refrigerated at the temperature of 2-8 ℃ for 24 hours, so that the layering effect is better. In addition, the solubility of both alcohol precipitation concentrations can be improved, but the yield of dry paste after alcohol precipitation is low, and the cost of alcohol precipitation is higher than that of water precipitation, so that water precipitation purification is finally selected.
Experiment 3: examination of hygroscopicity of particles
In order to ensure the stability of the particles, whether the particles are easy to absorb moisture is examined, and the critical relative humidity is measured by the following specific method: an appropriate amount of the particles of example 1 was weighed, and the particles having a thickness of about 2mm were placed on the bottom of a flat weighing bottle having a constant weight, accurately weighed, placed in a desiccator containing supersaturated solutions of different salts having different relative humidities (RH%) as shown in the following table, and kept in a constant temperature incubator at 25 ℃ for 72 hours, and then weighed to calculate the percentage of moisture absorption. The results are shown in Table 3
Table 3 examination of hygroscopicity of granules
The moisture absorption rate% in the table is plotted as ordinate and the relative humidity RH% is plotted as abscissa, the tangents at the two ends of the curve in the plot are plotted, and the abscissa corresponding to the intersection of the two tangents is the critical relative humidity, as shown in fig. 1.
As shown in fig. 1, the critical relative humidity of the granules is slightly greater than 65%, i.e. the environmental humidity should be controlled below 65% during granulation and packaging.
Experiment 4: and (3) inspecting the stability of the stranguria treating preparation:
accelerated stability tests were carried out according to the guidelines of the stability tests of the raw material drugs and the formulations in the "Chinese pharmacopoeia (fourth part) of the 2015 edition, and the test results are shown in Table 4:
table 4: expedition result table of accelerated stability test of stranguria treating preparation
As a result: as can be seen from the table, the gallic acid content of the stranguria preparation is higher by about 60 percent compared with that of the commercially available stranguria granule, and the stranguria preparation is more stable than the commercially available stranguria granule in terms of moisture, and the results of the products meet the requirements through accelerated test investigation.
In order to enable a person of ordinary skill in the art to better understand the present invention, the applicant conducted a series of animal experimental studies to prove the effects of the present invention:
the purpose of the test is as follows: the influence of the stranguria preparation on experimental acute pyelonephritis of rats is examined
60 SD rats with the weight of 200-250 g are anesthetized by intraperitoneal injection of pentobarbital sodium 3Omg/kg, fixed in prone position, cut at the back side, and the right kidney is fully exposed, and a 0.25 mL BCG (4 mL BCG) syringe with the volume of 0.25 mL is adopted#Needle) at the renal parenchyma, part 3, inoculation 107·mL-150. mu.l of the bacterial suspension. And after operation, the seeds are placed in a metabolism cage for independent feeding. A fresh urine sample 24 h after the operation is collected, the number of leucocytes in the urine sample is counted under a microscope by using a blood cell counting plate, and the number of leucocytes in the urine sample per cubic millimeter is more than 100, so that the bacterial nephritis model is considered to be successful. The model mice were randomly divided into 6 groups according to the number of leukocytes and sex in urine: the commercially available Neisseria gonorrhoeae granule group, the groups of examples 1 to 3 of the present invention, the norfloxacin group and the model group were used together with a normal control group (those not infected with bacteria). After the animals are grouped, the corresponding tested drugs are administrated by gastric lavage, the equal volume of normal saline is administrated by the model group, and the drug is continuously administrated for 7 d. Collecting urine samples before administration every day, and counting the number of leucocytes in the urine samples; urine samples of 1, 2, 3, 5 and 7 days after administration were collected from each group of animals and urine Protein (PRO), occult Blood (BLD), ketone body (KET), Bilirubin (BIL) and Urobilinogen (URO) were analyzed by a Japanese MA-4210 type urine analyzer. The results of the urinalysis were converted to the following criteriaFraction values: "-" score 1, "+" score 2, "+ + +" score 3, "+ + + + + + + + +" score 4, "+ + + + + + + + + + + + + + + + +" score 5, and the average score value for each group was determined. Statistical analysis is carried out by adopting a non-parameter method; the counting treatment of leucocyte in urine adopts t test to compare the difference between the administration group and the model group. The statistical processing is carried out by adopting computer SPSS software. The results are shown in tables 5 to 7.
TABLE 5 Effect of stranguria-treating preparation on urine leukocytes of rat with pyelonephritis
TABLE 6 Effect of drench preparation on PRO, BLD, KET, BIL, URO urine of rat on day 2
TABLE 7 Effect of drench preparation on PRO, BLD, KET, BIL, URO urine in rat on day 3
As can be seen from Table 5, the rat bacterial nephritis in the experiment can be recovered by itself, but the recovery of the stranguria preparation group is obviously better than that of the model group, and particularly the recovery of 3 example groups of the invention is better than that of the commercially available stranguria granule group; secondly, as can be seen from tables 6-7, the stranguria preparation can significantly reduce the amount of occult blood in urine of rats with bacterial nephritis, and the effect of the 3 example groups of the invention is better than that of the commercially available stranguria granule group. The stranguria treating preparation has certain treatment effect on experimental bacterial nephritis rats, and the curative effect is superior to that of the stranguria treating granules sold on the market.
Drawings
Fig. 1 is a graph of critical relative humidity of stranguria treating granules.
The abscissa in the figure represents the relative humidity of the environment and the ordinate represents the moisture absorption rate of the particles.
Detailed Description
Example 1:
prescription: polygonum capitatum 450g, plantain herb 225g, creeping oxalis 225g, and Boenninghausenia 150g
The preparation process comprises the following steps:
Example 2:
prescription: polygonum capitatum 450g, plantain herb 225g, creeping oxalis 225g, and Boenninghausenia 150g
The preparation process comprises the following steps:
Example 3:
prescription: polygonum capitatum 450g, plantain herb 225g, creeping oxalis 225g, and Boenninghausenia 150g
The preparation process comprises the following steps:
Example 4:
prescription: polygonum capitatum 450g, plantain herb 225g, creeping oxalis 225g, and Boenninghausenia 150g
The preparation process comprises the following steps:
Example 5:
prescription: polygonum capitatum 450g, plantain herb 225g, creeping oxalis 225g, and Boenninghausenia 150g
The preparation process comprises the following steps:
Claims (2)
1. The preparation method of the stranguria treating preparation comprises the following raw material medicines in parts by weight: 450 parts of polygonum capitatum, 225 parts of plantain, 225 parts of creeping oxalis and 150 parts of chinarue; the method specifically comprises the following steps:
2. The method of claim 1, wherein the dosage form is a granule, a capsule, a tablet, a pill, an oral solution.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911015428.2A CN111714551B (en) | 2019-10-24 | 2019-10-24 | Preparation method of stranguria-treating preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911015428.2A CN111714551B (en) | 2019-10-24 | 2019-10-24 | Preparation method of stranguria-treating preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111714551A CN111714551A (en) | 2020-09-29 |
| CN111714551B true CN111714551B (en) | 2021-10-15 |
Family
ID=72563931
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911015428.2A Active CN111714551B (en) | 2019-10-24 | 2019-10-24 | Preparation method of stranguria-treating preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111714551B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1768800A (en) * | 2005-09-29 | 2006-05-10 | 贵州百祥制药有限责任公司 | Chinese medicinal formulation for treating blennorrhagia and urinary system infection, and preparation method thereof |
| CN105434555A (en) * | 2015-12-30 | 2016-03-30 | 贵州弘康药业有限公司 | Production method of Relinqing preparation |
| CN110339277A (en) * | 2019-08-20 | 2019-10-18 | 广西万寿堂药业有限公司 | FUKE ZHIDAI PIAN and preparation method thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN191020B (en) * | 2000-03-28 | 2003-09-13 | Dabur Res Foundation | |
| CN104096163B (en) * | 2013-04-08 | 2018-01-05 | 韦建学 | The topical agent kept a public place clean for women ovary and internal vulva maintenance |
-
2019
- 2019-10-24 CN CN201911015428.2A patent/CN111714551B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1768800A (en) * | 2005-09-29 | 2006-05-10 | 贵州百祥制药有限责任公司 | Chinese medicinal formulation for treating blennorrhagia and urinary system infection, and preparation method thereof |
| CN105434555A (en) * | 2015-12-30 | 2016-03-30 | 贵州弘康药业有限公司 | Production method of Relinqing preparation |
| CN110339277A (en) * | 2019-08-20 | 2019-10-18 | 广西万寿堂药业有限公司 | FUKE ZHIDAI PIAN and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| Antibacterial and anti-inflammatory effects of extracts and fractions from Polygonum capitatum;Shang-Gao Liao等;《Journal of Ethnopharmacology》;20110204;第134卷(第3期);1006-1009 * |
| 热淋清颗粒对肾盂肾炎模型大鼠的药效学研究;李孟林等;《中国中药杂志》;20060131;第31卷(第02期);153-155 * |
| 葛花解饮颗粒的研制;崔敬爱;《中国西部科技》;20081231;第07卷(第34期);28-30 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111714551A (en) | 2020-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100425277C (en) | Composition with function of relieving cough and calming asthma and preparing method | |
| CN111358839B (en) | Formula granules of polygonum capitatum and preparation method thereof | |
| CN1872106A (en) | Application of wild basil circle leaves in treating disease of virulence cold | |
| CN114081906B (en) | Traditional Chinese medicine composition for treating constipation and preparation method thereof | |
| CN105031197B (en) | A kind of Chinese medicine composition and the preparation method and application thereof with throat soothing function of moistening and cleaning throat | |
| CN109091530B (en) | Application of perilla leaf extract in preventing or treating aplastic anemia | |
| CN111714551B (en) | Preparation method of stranguria-treating preparation | |
| CN110664883B (en) | A pharmaceutical composition with vital essence generation effect | |
| CN113730464A (en) | New application of rhizoma coptidis pill, extract and pharmaceutical composition thereof and rhizoma coptidis pill product | |
| CN115105502B (en) | Application of compound containing stephania plant alkaloid in preparation of cat infectious peritonitis medicine | |
| CN106310017B (en) | Traditional Chinese medicine granule for treating diffuse interstitial pulmonary fibrosis lung and kidney qi deficiency syndrome | |
| CN100558379C (en) | Shuang Huang Lian ' dispersible tablet and preparation method thereof | |
| CN1947749B (en) | Medicine composition containing Poria cocos and Touhualiao (polygonaceae) | |
| CN106581520B (en) | Traditional Chinese medicine granule for treating diffuse interstitial pulmonary fibrosis lung qi deficiency syndrome | |
| CN114931565A (en) | Preparation method of quassia atomization inhalation solution | |
| CN101249223A (en) | Chinese native medicine and western medicine compound preparations for curing coryza cold | |
| CN101161262B (en) | A medicine for treating chronic renal failure and its preparing method | |
| CN104042928B (en) | A kind of pharmaceutical composition for treating diabetes and its production and use | |
| CN102824423B (en) | Medicinal composition comprising albiflorin and arctiin and application | |
| CN1069534C (en) | Preparation method for medicine of reducing blood sugar using natural bitter gourd extract | |
| CN103505628B (en) | A kind of application of Chinese medicine composition in preparing treatment ketoacidosis and merging leukemoid reaction medicine | |
| CN102362993B (en) | Chinese medicinal preparation with effects of protecting intestines and removing toxic materials, and preparation method thereof | |
| CN111658708A (en) | Composition for improving anemia symptoms and preparation method and application thereof | |
| CN111714568B (en) | Preparation method of Fuyanxiao preparation | |
| CN100367934C (en) | Yin-nourishing lung-heat clearing drop pills |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |